U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-extends-review-period-blenrep-belantamab-mafodotin-rrmm)